Readers of Real Money sometimes email me with questions about stocks they are interested in. Time permitting, I make an effort to respond to all emails. Most of the time I just respond to the subscriber but sometimes the stock catches my attention. One subscriber asked about what I thought of Immunomedics (IMMU) . The company is a clinical-stage biopharmaceutical company that is "developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases".
Let's check out the charts of this cutting edge company to see what the upside or the downside looks like.